Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii

K. Y. Look, F. B. Stehman, D. H. Moore, G. P. Sutton

Research output: Contribution to journalArticle

3 Scopus citations


Pseudomyxoma peritoneii has an indolent course but a 5-year survival rate of 40-45%. The role for postoperative intraperitoneal chemotherapy is unclear. Nine patients with pseudomyxoma arising from mucinous neoplasms of the ovary and intestinal tract received a total of 89 courses of intraperitoneal 5-fluorouracil (IPSFU). Each course consisted of eight 4-h exchanges of I g of 5FU in 2 1 of 1.5% Inpersol ®. Median follow-up after diagnosis was 30 months (range 6-74). All patients were evaluable for toxicity and response. There was one treatment-related death due to renal failure and sepsis. Three patients developed disease progression prior to scheduled second-look laparotomy. At second-look laparotomy two patients demonstrated pathologic complete responses, one had stable disease and one had progression of disease. One patient remained clinically free of progression after refusing second-look laparotomy. The projected 5-year survival by Kaplan-Meier estimate was 87% for patients treated with IP5FU compared to a 52% 5-year survival seen in a series of 11 patients treated prior to the use of IPSFU (P = 0.12). This preliminary analysis suggests that IPFU in the described schedule fails to improve survival statistically compared to previously used regimens for patients with pseudomyxoma peritoneii.

Original languageEnglish (US)
Pages (from-to)361-365
Number of pages5
JournalInternational Journal of Gynecological Cancer
Issue number5
StatePublished - Sep 1995


  • Intraperitoneal 5-fluorouracil
  • Pseudomyxoma peritoneii

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii'. Together they form a unique fingerprint.

  • Cite this